Table 2 Clinicopathologic patient characteristics and associations with immune cell density in the TP25μm zone at the tumour centre in cohort 2. Tumour budding is scored according to the 10-high-power-fields method [24]. Abbreviation: GZMB granzyme B
CD8 | GZMB | CD68 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Overall | low (%) | high (%) | p | low (%) | high (%) | p | low (%) | high (%) | p | |
n | 136 | 68 | 68 | 68 | 68 | 68 | 68 | |||
Age (n = 136) | ||||||||||
Mean (SD) | 67.8 (14.9) | 69.5 (14.5) | 66.1 (15.2) | 0.186 | 69.3 (13.7) | 66.3 (16.0) | 0.237 | 68.4 (14.9) | 67.1 (15.0) | 0.614 |
Gender (n = 136) | ||||||||||
Female | 59 (43.4) | 29 (42.6) | 30 (44.1) | 1 | 31 (45.6) | 28 (41.2) | 0.729 | 25 (36.8) | 34 (50.0) | 0.166 |
Male | 77 (56.6) | 39 (57.4) | 38 (55.9) | 37 (54.4) | 40 (58.8) | 43 (63.2) | 34 (50.0) | |||
Location (n = 136) | ||||||||||
Right | 67 (49.3) | 33 (48.5) | 34 (50.0) | 1 | 32 (47.1) | 35 (51.5) | 0.732 | 30 (44.1) | 37 (54.4) | 0.303 |
Left | 69 (50.7) | 35 (51.5) | 34 (50.0) | 36 (52.9) | 33 (48.5) | 38 (55.9) | 31 (45.6) | |||
pT (n = 136) | ||||||||||
3 | 114 (83.8) | 53 (77.9) | 61 (89.7) | 0.103 | 52 (76.5) | 62 (91.2) | 0.036 | 55 (80.9) | 59 (86.8) | 0.485 |
4 | 22 (16.2) | 15 (22.1) | 7 (10.3) | 16 (23.5) | 6 (8.8) | 13 (19.1) | 9 (13.2) | |||
Tumour Grade (n = 136) | ||||||||||
1-2 | 126 (92.6) | 65 (95.6) | 61 (89.7) | 0.324 | 66 (97.1) | 60 (88.2) | 0.1 | 64 (94.1) | 62 (91.2) | 0.743 |
3 | 10 (7.4) | 3 (4.4) | 7 (10.3) | 2 (2.9) | 8 (11.8) | 4 (5.9) | 6 (8.8) | |||
Venous Invasion (n = 136) | ||||||||||
0 | 111 (86.7) | 54 (85.7) | 57 (87.7) | 0.945 | 53 (84.1) | 58 (89.2) | 0.555 | 53 (86.9) | 58 (86.6) | 1 |
1 | 17 (13.3) | 9 (14.3) | 8 (12.3) | 10 (15.9) | 7 (10.8) | 8 (13.1) | 9 (13.4) | |||
Tumour Budding (n = 136) | ||||||||||
0 | 98 (72.1) | 48 (70.6) | 50 (73.5) | 0.848 | 45 (66.2) | 53 (77.9) | 0.181 | 53 (77.9) | 45 (66.2) | 0.181 |
1 | 38 (27.9) | 20 (29.4) | 18 (26.5) | 23 (33.8) | 15 (22.1) | 15 (22.1) | 23 (33.8) | |||